EU wants views on new orphan medicines guidance
Comments should be made by 30 September to the European Commission
European pharmaceutical companies have been asked to comment on planned guidance on the format and content of applications for designating products as orphan medicinal products and on transferring such designations between companies. This includes detail on the pharmaceutical, its producer, the condition it treats, target consumers and more.
Comments should be made by 30 September to the European Commission.